Meet the Humira Team
Analysis Group supports our clients in biopharmaceutical companies at every stage, from guiding design of Phase I clinical studies to developing evidence strategy for mature products. One prominent product that our teams have supported from the beginning of its development and throughout its product life cycle is Humira, an immunosuppressive biologic drug. Humira treats a range of diseases in dermatology, gastroenterology, and rheumatology such as plaque psoriasis, hidradenitis suppurativa, inflammatory bowel diseases, and rheumatoid arthritis, among others.
Our Humira project teams conduct crucial research and data analysis to provide valuable input throughout the product development and marketing life cycle. The teams engage across offices internationally in a wide variety of research and analysis, including analyzing clinical trials, assessing the impacts of autoimmune diseases on quality of life, engaging in strategic planning, and helping to secure approval from regulatory agencies in the US and in countries around the world. With their diverse backgrounds, the Humira team has developed innovative and cutting-edge solutions, many of which have become industry standards in health economics and outcomes research (HEOR).
“I have had the opportunity to support the development of Humira and research relating to the diseases it treats since very early in the product life cycle. Successful partnerships like this one rely on strategic and creative thinking, development of innovative methodologies, and work of the highest quality. Together, Humira team members have achieved outstanding results. Our support of Humira has also provided an opportunity for many of our junior staff to develop their skills while taking part in cutting-edge research.”
– Eric Wu, Managing Principal, Boston
Humira Case Studies
- Conducting a Network Meta-analysis (NMA)Project #1: Establishing a new standard for comparing data across clinical trials
- Securing Regulatory Agency Approval and ReimbursementProject #2: Determining the validity of a measurement for treatment efficacy
- Evaluating Costs of TreatmentProject #3: Assessing the impacts of switching or stopping treatment on health care outcomes